Biosimilar strategic implementation at a large health system

Kar, Indrani; Kronz, Margaret; Kolychev, Evelina; Silverman, Paula; Mendiratta, Prateek; Tomlinson, Benjamin; Prunty, Jeremy; Copley, Melissa; Patel, Seema; Caudill, Sara; Farah, Lisa; Wesolowski, Bryan; Crissinger, Tyler; Kendig, Colin; Szymczak, Eric; Duraj, Lindsey; Acheson, Emily Sohanna; Lyamkin, Svetlana; Dumot, John A.; King, Michelle; Mocilnikar, Allyson; Cunningham, Kevin; Paulic, Nikola; Botzki, Uwe; Lerman, Rachael M.; Strosaker, Robyn; Osborne, Shawn; Glotzbecker, Brett

doi:10.1093/ajhp/zxab410

Cited by 8 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite challenges, clinics and hospital systems are becoming more adept at implementing biosimilars into practice. 19 , 20 The increasing adoption of biosimilars contributes to the overall decreasing drug costs for clinics and hospitals ( Table 2 .) 19 , 20 Expenditures for bevacizumab, rituximab, and trastuzumab illustrate the influence of biosimilars on drug expenditures.…”

Section: Discussionmentioning

confidence: 99%

“… 19 , 20 The increasing adoption of biosimilars contributes to the overall decreasing drug costs for clinics and hospitals ( Table 2 .) 19 , 20 Expenditures for bevacizumab, rituximab, and trastuzumab illustrate the influence of biosimilars on drug expenditures. In 2018, expenditures for those 3 key oncology therapeutics in the clinic setting totaled approximately $7.7 billion; in 2019, after 4 biosimilars for bevacizumab, trastuzumab, and rituximab were launched, total expenditures for the 3 reference products decreased to $5.4 billion.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

National trends in prescription drug expenditures and projections for 2022

Tichy

Hoffman

Suda

et al. 2022

American Journal of Health-System Pharmacy

View full text Add to dashboard Cite

Disclaimer In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. Purpose To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug spending in 2022 in the United States, with a focus on the nonfederal hospital and clinic sectors. Methods Historical patterns were assessed by examining data on drug purchases from manufacturers using the IQVIA National Sales Perspectives database. Factors that may influence drug spending in hospitals and clinics in 2022 were reviewed—including new drug approvals, patent expirations, and potential new policies or legislation. Focused analyses were conducted for biosimilars, cancer drugs, generics, COVID-19 pandemic influence, and specialty drugs. For nonfederal hospitals, clinics, and overall (all sectors), estimates of growth of pharmaceutical expenditures in 2022 were based on a combination of quantitative analyses and expert opinion. Results In 2021, overall pharmaceutical expenditures in the US grew 7.7% compared to 2020, for a total of $576.9 billion. Utilization (a 4.8% increase), price (a 1.9% increase) and new drugs (a 1.1% increase) drove this increase. Adalimumab was the top drug in terms of overall expenditures in 2021, followed by apixaban, and dulaglutide. Drug expenditures were $39.6 billion (a 8.4% increase) and $105.0 billion (a 7.7% increase) in nonfederal hospitals and in clinics, respectively. In clinics and hospitals, new products and increased utilization growth drove growth, with decreasing prices for both sectors acting as an expense restraint. Several new drugs that are likely to influence spending are expected to be approved in 2022. Specialty and cancer drugs will continue to drive expenditures along with the evolution of the COVID-19 pandemic. Conclusion For 2022, we expect overall prescription drug spending to rise by 4.0% to 6.0%, whereas in clinics and hospitals we anticipate increases of 7.0% to 9.0% and 3.0% to 5.0%, respectively, compared to 2021. These national estimates of future pharmaceutical expenditure growth may not be representative of any particular health system because of the myriad of local factors that influence actual spending.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

National trends in prescription drug expenditures and projections for 2022

Tichy

Hoffman

Suda

et al. 2022

American Journal of Health-System Pharmacy

View full text Add to dashboard Cite

show abstract

“…One such example occurs in the area of biosimilar medications because these agents present multiple challenges for health systems 28 . Health‐system DIS evaluates efficacy, safety, cost, insurance coverage, reimbursement, and operational impact to health‐system inpatient and infusion areas for new biosimilar agents as well as provider/patient communication strategies to optimize adoption 28 . Health‐system DIS may have direct contact with sales representatives or work closely with designated pharmacy buyers or supply chain specialists to continuously assess financial contracts.…”

Section: Practice Areasmentioning

confidence: 99%

From education to practice—2024 update: An opinion paper of the Drug Information Practice and Research Network of the American College of Clinical Pharmacy

Johnson,

Goldwire,

Abdalla

et al. 2024

J Am Coll Clin Pharm

View full text Add to dashboard Cite

Drug information specialists (DIS) bring unique, specialized expertise and provide services in diverse settings including health systems, academia, pharmaceutical industry, compendia, medical writing, and other areas. With widespread access to drug information (DI) resources through user‐friendly, online platforms, the role of DIS has shifted. Core skill sets once confined to DIS are now distributed across various non‐DIS clinical specialties. DIS have transformed the application of their specialized skill set and adapted it to a variety of traditional and nontraditional areas, providing and applying advanced expertise to solve a variety of contemporary challenges. The training of students and residents has evolved to include evidence‐based practical contemporary methods that promote critical thinking and reasoning. Effective DI evaluation and communication necessitates customizing content for stakeholders to ensure understanding and contribute to optimal patient care, all while addressing misinformation and disinformation. The future of DI as a specialty is bright, with ever‐increasing recognition of the importance of DI skills in non‐DIS practitioners. DIS will likely continue to guide best practices in the education/training of new practitioners and continue to provide advanced services and formulary analytics. This update to our 2009 DI PRN Opinion paper will focus on: (1) DI education and training needed for all students, residents, and pharmacists; (2) career opportunities, roles, and responsibilities specifically tailored for DIS in health systems, managed care organizations, academia, pharmaceutical/biotechnology industry, and medical writing services; and (3) the future direction of DI, including the potential impact of artificial intelligence.

show abstract

“…18 A detailed discussion of these challenges and potential solutions is beyond the scope of the current review but is available in recent publications on the implementation of biosimilars in clinical settings. [19][20][21][22]…”

Section: Challenges In Biosimilar Use and Uptakementioning

confidence: 99%